Compare · ARGX vs EIKN
ARGX vs EIKN
Side-by-side comparison of argenx SE (ARGX) and Eikon Therapeutics Inc. (EIKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and EIKN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.51B, about 118.2x EIKN ($452.6M).
- Over the past year, ARGX is up 54.7% and EIKN is down 43.1% - ARGX leads by 97.8 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 6 for EIKN).
- Company
- argenx SE
- Eikon Therapeutics Inc.
- Price
- $889.32+3.20%
- $8.42+0.66%
- Market cap
- $53.51B
- $452.6M
- 1M return
- +9.36%
- -26.91%
- 1Y return
- +54.68%
- -43.15%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2026
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 6
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest EIKN
- Eikon Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
- Eikon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
- Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
- SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.
- SEC Form 10-Q filed by Eikon Therapeutics Inc.
- Eikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates